Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;58(4):230-238.
doi: 10.1053/j.seminhematol.2021.10.006. Epub 2021 Oct 25.

Thrombotic manifestations of VEXAS syndrome

Affiliations
Review

Thrombotic manifestations of VEXAS syndrome

Emma M Groarke et al. Semin Hematol. 2021 Oct.

Abstract

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described autoinflammatory syndrome characterized by diffuse inflammatory manifestations, predisposition to hematological malignancy, and an association with a high rate of thrombosis. VEXAS is attributed to somatic mutations in the UBA1 gene in hematopoietic stem and progenitor cells with myeloid restriction in mature forms. The rate of thrombosis in VEXAS patients is approximately 40% in all reported cases to date. Venous thromboembolism predominates thrombotic events in VEXAS. These are classified as unprovoked in etiology, although systemic and vascular inflammation are implicated. Here, we review the clinical and laboratory characteristics in VEXAS that provide insight into the possible mechanisms leading to thrombosis. We present knowledge gaps in the mechanisms and management of VEXAS-associated thromboinflammation and propose areas for future investigation in the field.

Keywords: Antiphospholipid syndrome; Autoimmune; Coagulation; Inflammation; Innate immune; Lupus anticoagulant; Monocyte; Myelodysplastic syndrome; Neutrophil; Thrombosis; Ubiquitin; VEXAS.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Yogendra Kanthi is an inventor on a pending patent to the University of Michigan on the use of biogases in vascular disease. Emma M. Groarke and Alina E. Dulau-Florea have no disclosures relevant to this manuscript.

Publication types

Substances